Background Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small cell lung cancer (NSCLC). The aim of this study was to clarify the pathologic characteristics and long-term survival after surgical treatment in patients with PSC. Methods From January 2003 to December 2013, we retrospectively reviewed the clinical findings, surgical notes, and pathologic and follow-up data from 148 consecutive patients who underwent curative resection for PSC in 5 institutions. The Kaplan-Meier method, log-rank test, and Cox regression analysis were used. Results Mean age and male to female ratio were 66.6 ± 9.9 years and 120:28, respectively. Surgical resection (pneumonectomy in 8 patients, bilobectomy in 132 patients, and sublobar resection in 8 patients) was complete in 142 cases (96%). At pathologic evaluation, 36 patients (24%) had stage I, 69 patients (47%) had stage II, 33 patients (22%) had stage III, and 10 patients (7%) had stage IV disease. A “biphasic tumor” (PSC with an NSCLC component) was observed in 77 patients (52%). We detected a high rate of vascular emboli in the surgical specimens (overall, 68%; 57% in pathologic stage I tumors), whereas lymphatic emboli were found in 30% of cases (5% of pathologic stage I tumors). Overall median and 5-year long-term survival (LTS) was 19 months and 12.6% (LTS, 16.3% in pathologic stage I), respectively. Distant recurrences frequently occurred after surgical treatment (81%), even in pathologic stage I tumors that underwent R0 resection (62%). Multivariable survival analysis identified R+ resection (hazard ratio [HR],12.3; 95% confidence interval [CI], 3.67–41.28; p < 0.0001), advanced pathologic stage (HR, 5.75; 95% CI, 2.55–12.98; p < 0.0001), and the presence of vascular emboli (HR, 1.67; 95% CI, 1.05–2.67; p = 0.0327) as independent negative prognostic factors. Conclusions PSCs have very aggressive behavior and high metastatic potential even in early stages. R+ resection, pathologic TNM status, and the presence of vascular emboli are independent prognostic factors

Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis / 56) Lococo, F; Rapicetta, C; Cardillo, G; Stefani, A; Margaritora, S; Leuzzi, G; Rossi, G; Ciavarella, L; Morandi, U; Facciolo, F; Ricchetti, T; Cesario, A; Paci, M.. - In: ANNALS OF THORACIC SURGERY. - ISSN 0003-4975. - 103:4(2017), pp. 1142-1150. [10.1016/j.athoracsur.2016.08.114]

Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis

Stefani A;Morandi U;
2017

Abstract

Background Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small cell lung cancer (NSCLC). The aim of this study was to clarify the pathologic characteristics and long-term survival after surgical treatment in patients with PSC. Methods From January 2003 to December 2013, we retrospectively reviewed the clinical findings, surgical notes, and pathologic and follow-up data from 148 consecutive patients who underwent curative resection for PSC in 5 institutions. The Kaplan-Meier method, log-rank test, and Cox regression analysis were used. Results Mean age and male to female ratio were 66.6 ± 9.9 years and 120:28, respectively. Surgical resection (pneumonectomy in 8 patients, bilobectomy in 132 patients, and sublobar resection in 8 patients) was complete in 142 cases (96%). At pathologic evaluation, 36 patients (24%) had stage I, 69 patients (47%) had stage II, 33 patients (22%) had stage III, and 10 patients (7%) had stage IV disease. A “biphasic tumor” (PSC with an NSCLC component) was observed in 77 patients (52%). We detected a high rate of vascular emboli in the surgical specimens (overall, 68%; 57% in pathologic stage I tumors), whereas lymphatic emboli were found in 30% of cases (5% of pathologic stage I tumors). Overall median and 5-year long-term survival (LTS) was 19 months and 12.6% (LTS, 16.3% in pathologic stage I), respectively. Distant recurrences frequently occurred after surgical treatment (81%), even in pathologic stage I tumors that underwent R0 resection (62%). Multivariable survival analysis identified R+ resection (hazard ratio [HR],12.3; 95% confidence interval [CI], 3.67–41.28; p < 0.0001), advanced pathologic stage (HR, 5.75; 95% CI, 2.55–12.98; p < 0.0001), and the presence of vascular emboli (HR, 1.67; 95% CI, 1.05–2.67; p = 0.0327) as independent negative prognostic factors. Conclusions PSCs have very aggressive behavior and high metastatic potential even in early stages. R+ resection, pathologic TNM status, and the presence of vascular emboli are independent prognostic factors
2017
24-dic-2016
103
4
1142
1150
Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis / 56) Lococo, F; Rapicetta, C; Cardillo, G; Stefani, A; Margaritora, S; Leuzzi, G; Rossi, G; Ciavarella, L; Morandi, U; Facciolo, F; Ricchetti, T; Cesario, A; Paci, M.. - In: ANNALS OF THORACIC SURGERY. - ISSN 0003-4975. - 103:4(2017), pp. 1142-1150. [10.1016/j.athoracsur.2016.08.114]
56) Lococo, F; Rapicetta, C; Cardillo, G; Stefani, A; Margaritora, S; Leuzzi, G; Rossi, G; Ciavarella, L; Morandi, U; Facciolo, F; Ricchetti, T; Cesario, A; Paci, M.
File in questo prodotto:
File Dimensione Formato  
Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors. a multicenter analysis.pdf

Open access

Descrizione: articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 2.24 MB
Formato Adobe PDF
2.24 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1150856
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact